Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Hemay005 in Healthy Subjects
NCT03570346Phase 1Unknown
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mufemilast in psoriasis (4 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Number of adverse events and serious adverse events. Status: unknown.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03570346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570346.